Open Access

Brijesh Kumar

• Glucose homeostasis is tightly regulated by insulin production from ß-cells and glucagon production from α-cells. Changes in the balance of these hormones lead to Diabetes Mellitus (DM), which is foreseen to be the 7th leading cause of death by 2030, warranting a high demand to identify new therapeutics. DM is characterized by a reduction in ß-cell mass and reduced insulin production from ß-cells. α-cell development and fate mainly depend on the activity of the homeodomain-containing transcription factor Aristaless related homeobox (Arx). Conditional loss- of- function of Arx in α-cells leads to their conversion into functional insulin-producing ß-cells and thus an expansion of ß-cell mass. Therefore, inhibition of Arx is an interesting target for the expansion of ß-cells. The zebrafish model provides a fast, cost-effective and reliable translational platform for drug discovery in an in vivo setting. Here, we screened ~6217 small molecules on a transgenic zebrafish line (TgBAC(arxa:Luc2)) in which the arx promoter drives the expression of the luciferase gene which allows a sensitive and quantitative readout of promoter activity. Small molecule screening allowed us to identify 36 candidate repressors of arxa promoter activity. Furthermore, we started to validate these candidates in other assays. Preliminary results showed that DMAT (a potent CK2 inhibitor) and CNS-1102 (NMDA receptor inhibitor) increase functional ß-cell regeneration. By lineage tracing α-cells during ß-cell regeneration, we could show that both DMAT and CNS-1102 promote α- to ß-cell transdifferentiation. Here, we propose that Casein kinase II and NMDA receptor as potential molecular targets that could be exploited for the treatment of diabetes by generating functional beta-cells from the non-beta-cell progenitor, particularly alpha-cells in situ.